Evaluating convalescent plasma therapy in severe COVID-19: a retrospective cohort study
The Journal of Infection in Developing Countries · 2024
DOI: 10.3855/jidc.19859 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift The Journal of Infection in Developing Countries, 2024. Verfasst von Masoud Moeini Taba und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran. Hauptthemen laut MEDLINE: COVID-19, Immunization, Passive. Die Arbeit wurde bisher 3-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Convalescent plasma (CP) therapy is a form of passive immunization which has been used as a treatment for coronavirus disease 2019 (COVID-19). This study aims to evaluate the efficacy and safety of CP therapy in patients with severe COVID-19. Methodology: In this retrospective cohort study, 50 patients with severe COVID-19 treated with CP at Shahid Beheshti Hospital, Kashan, in 2019 were evaluated. Eligible plasma donors were COVID-19 survivors with high IgG levels and no comorbidities. Clinical and laboratory parameters, including vital signs, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and white blood cell (WBC) levels, were measured before and after CP therapy at specified intervals including 24 h and 48 h post-therapy.
Results
The average age of the patients was 55.96 years, and 46% had comorbidities. No adverse effects from CP therapy were reported. Significant associations were observed between baseline ESR levels and factors such as age, comorbidities, hypertension history, and intubation status. However, there was no significant correlation between the outcomes of WBC, ESR, and CRP levels and the IgG levels in recipients.
Conclusions
CP therapy appears to be a safe and potentially effective treatment for severe COVID-19, especially in patients with certain baseline characteristics. These findings add valuable insights into the management of severe COVID-19 cases, although further research is needed to fully understand the implications and optimize treatment protocols.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Microbiology and Immunology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
- Student Research Committee, Kashan University of Medical Sciences, Kashan, Iran.
- Department of Community Medicine, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
- Department of Pharmacology, School of Medicine, Kashan University of Medical Sciences, Kashan, Iran.
Zitieren
APA
Moeini Taba, M., Eshraghi, R., Zare Tutestani, M., Moraveji, S. A., Sehat, M., & Banafshe, H. R. (2024). Evaluating convalescent plasma therapy in severe COVID-19: a retrospective cohort study. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.19859
Vancouver
Moeini Taba M, Eshraghi R, Zare Tutestani M, Moraveji SA, Sehat M, Banafshe HR. Evaluating convalescent plasma therapy in severe COVID-19: a retrospective cohort study. The Journal of Infection in Developing Countries. 2024. doi:10.3855/jidc.19859
BibTeX
@article{MoeiniTaba2024,
author = {Moeini Taba, Masoud and Eshraghi, Reza and Zare Tutestani, Maryam and Moraveji, Sayyed Alireza and Sehat, Mojtaba and Banafshe, Hamid Reza},
title = {Evaluating convalescent plasma therapy in severe COVID-19: a retrospective cohort study},
journal = {The Journal of Infection in Developing Countries},
year = {2024},
doi = {10.3855/jidc.19859}
}
EUVIMED